Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 274

1.

Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients.

Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM; SUCCESS VI Study Group.

Am J Ther. 2001 Mar-Apr;8(2):85-95. Erratum in: Am J Ther 2001 May-Jun;8(3):220.

PMID:
11304662
2.

Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis.

Whelton A, White WB, Bello AE, Puma JA, Fort JG; SUCCESS-VII Investigators.

Am J Cardiol. 2002 Nov 1;90(9):959-63.

PMID:
12398962
3.

The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.

Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG; Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators.

Arch Intern Med. 2005 Jan 24;165(2):161-8. Erratum in: Arch Intern Med. 2005 Mar 14;165(5):551.

PMID:
15668361
7.
8.
11.

Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.

Schwartz JI, Vandormael K, Malice MP, Kalyani RN, Lasseter KC, Holmes GB, Gertz BJ, Gottesdiener KM, Laurenzi M, Redfern KJ, Brune K.

Clin Pharmacol Ther. 2002 Jul;72(1):50-61.

PMID:
12152004
13.
14.

Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.

Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.

Am J Manag Care. 2002 Oct;8(15 Suppl):S414-27.

15.

Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors.

Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.

Am J Manag Care. 2002 Oct;8(15 Suppl):S401-13.

16.

Blood pressure in Native Americans switched from celecoxib to rofecoxib.

Fredy J, Diggins DA Jr, Morrill GB.

Ann Pharmacother. 2005 May;39(5):797-802. Epub 2005 Mar 29.

PMID:
15797981
17.

Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial.

Lisse JR, Perlman M, Johansson G, Shoemaker JR, Schechtman J, Skalky CS, Dixon ME, Polis AB, Mollen AJ, Geba GP; ADVANTAGE Study Group.

Ann Intern Med. 2003 Oct 7;139(7):539-46.

PMID:
14530224
18.

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.

Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J.

Circulation. 2004 May 4;109(17):2068-73. Epub 2004 Apr 19.

19.
20.

An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis.

Schnitzer TJ, Kong SX, Mitchell JH, Mavros P, Watson DJ, Pellissier JM, Straus WL.

Clin Ther. 2003 Dec;25(12):3162-72.

PMID:
14749154

Supplemental Content

Support Center